#VisualAbstract: Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
Tag: lung cancer
Multicancer early detection blood tests show promise but warrant further clinical evaluation
1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2. Patients in the true-positive group ...
Adenocarcinoma is the most prevalent lung cancer subtype and has a greater incidence rate in males than females
1. The second greatest burden of lung cancer worldwide is attributed to squamous cell carcinoma 2. Large cell carcinoma represents ...
#VisualAbstract: Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...
Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...
#VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients ...
Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients ...
#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://www.2minutemedicine.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-350x250.jpg)
Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
#VisualAbstract: Lobar vs Sublobar Resection for Peripheral Stage IA NSCLC
1. The 5-year disease-free survival, overall survival, and recurrence rates were similar in both lobar vs sublobar resections for patients ...
